Pharmaceutical - Respiratory and Pulmonary, Johnson & Johnson


Popular Filters

EU approval for Janssen-Cilag's Dacogen and Novartis/Vectura's Seebri Breezhealer


The European Commission on Friday approved the marketing authorization for Janssen-Cilag's (a unit of…

Astex PharmaceuticalsDacogenEuropeJanssen-CilagJohnson & JohnsonNovartisOncologyPharmaceuticalRegulationRespiratory and PulmonarySeebri BreezhalerVectura

Strong results for Bayer's Xarelto in treating pulmonary blood clots


German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

Caelyx and Ceplene manufacturing should be moved, says EMA


The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

Janssen drops deal with Orexo for OX-CLI/OX-ESI


US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Johnson & Johnson stops Doribax trial; reportedly agrees Risperdal settlement


The US Food and Drug Administration says that a recent clinical trial with Doribax (doripenem) being…

DoribaxFinancialJanssenJohnson & JohnsonLegalNeurologicalNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRisperdal

Back to top